巴戟天寡糖对抑郁症患者血浆IL-6和TNF-α的影响

Effects of morinda officinalis oligose on plasma IL-6 and TNF-α levels in patients with depression

目的:探讨巴戟天寡糖对抑郁症患者血浆白细胞介素-6(interleukin-6,IL-6)和肿瘤坏死因子-α(tumor necrosis factor,TNF-α)的影响及其与临床疗效的关系。方法:本研究入组符合国际疾病分类第10版(ICD-10)抑郁发作诊断标准的门诊患者32例,入组后单一巴戟天寡糖胶囊治疗,疗程8周,每2周访视1次,评估患者的抑郁症状变化及药物安全性。疗效标准为汉密尔顿抑郁量表(hamilton depression rating scale-17,HAMD-17)总分变化。入组前后各采血1次,采用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)测定患者治疗前后血浆IL-6及TNF-α的浓度变化。对患者治疗前后血浆IL-6及TNF-α的浓度变化与疗效及安全性指标进行关联分析,探讨巴戟天寡糖胶囊抗抑郁作用可能的潜在药理学机制。结果:巴戟天寡糖胶囊抗抑郁治疗后,入组患者在第2,4,6和8周末HAMD-17评分均显著降低(均P <0. 01);治疗后血浆IL-6和TNF-α浓度均显著下降(均P <0. 01);对治疗有效组和无效组进行协方差分析。结果显示,治疗后有效组和无效组血浆IL-6及TNF-α浓度均无统计学差异(均P>0. 05)。结论:巴戟天寡糖胶囊可以改善抑郁症患者的抑郁症状,巴戟天寡糖可降低抑郁症患者血浆IL-6和TNF-α水平。

Objective:To investigate the effects of morinda officinalis oligose on plasma interleukin-6(IL-6)and tumor necrosis factor(TNF-α)levels in patients with depression.Methods:Thirty-two patients who had a diagnosis of major depression according to international classification of diseases-10(ICD-10)were included and treated with morinda officinalis oligoes for 8 weeks.Changes of depressive symptoms and side reactions were assessed biweekly.Hamilton depression rating scale-17(HAMD-17)were employed to the main efficacy criteria.The plasma levels of IL-6 and TNF-αbefore and after the treatment were measured by enzyme-linked immunosorbent assay(ELISA).By correlating the changes of plasma levels of IL-6 and TNF-αwith efficacy and safety indicators,we investigated the potential pharmacological mechanism of morinda officinalis oligoes.Results:HAMD-17 scores decreased significantly after 2,4,6 and 8 weeks of treatment(P<0.01).Compared with baseline,significant effectwas observed on plasma levels of IL-6 and TNF-αafter morinda officinalis oligose treatment(P<0.01).The covariance analysis revealed,no differences were observed in plasma levels of IL-6 and TNF-αbetween the patients with and without response to morinda officinalis oligoes(P>0.05).Conclusion:Morinda officinalis oligose can improve depressive symptoms and decrease IL-6 and TNF-αlevels.